Summary: Researchers have identified a promising drug target for Fragile X syndrome, the most common genetic cause of autism and intellectual disability. The study shows that loss of the FMR1 gene triggers an abnormal, widespread increase of a synapse-localized protein called EPAC2 across multiple brain cell types.
In mouse models of Fragile X, blocking EPAC2—either genetically or with a pharmacological antagonist—restored disrupted cortical circuit activity and reversed core behavioral features such as tactile hypersensitivity, social interaction difficulties, and elevated seizure risk.
Key Facts
- The Single-Gene Cause: Fragile X syndrome is caused by mutation of the FMR1 gene, which stops production of a protein essential for normal brain development and function. The condition affects roughly 1 in 2,000 boys.
- EPAC2 Identified: RNA sequencing in genetically engineered mice lacking FMR1 revealed that the gene Rapgef4 (also known as EPAC2) is upregulated at synapses. EPAC2 plays established roles in synaptic signaling, learning and memory.
- Restoring Cell Balance: Fragile X is thought to stem from an imbalance between excitatory and inhibitory neurons. While FMR1 loss impacts these cell classes differently, EPAC2 was consistently elevated across both excitatory and inhibitory neurons, making it a promising unified therapeutic target.
- Brain-Restricted Expression: EPAC2 expression is largely confined to the brain, which reduces the likelihood that EPAC2-targeting drugs will produce widespread off-target effects in other organs.
- Relevance Beyond Early Development: EPAC2 levels increase as the brain matures, suggesting that therapies aimed at EPAC2 could be effective not only in infancy but also for older children, adolescents, and adults living with Fragile X syndrome.
Source: UCLA
UCLA Health researchers have pinpointed EPAC2 as a potential therapeutic target for Fragile X syndrome, the leading monogenic cause of intellectual disability and a frequent genetic contributor to autism spectrum disorder.
Fragile X syndrome arises when a mutation in the FMR1 gene halts production of a protein that normally regulates synaptic development and function. Individuals with Fragile X commonly experience intellectual disability, attention deficits, social communication challenges, heightened sensitivity to sensory input like sound and touch, and an increased risk of seizures. Many meet diagnostic criteria for autism spectrum disorder.
Because Fragile X results from a single-gene defect, the disorder has long been considered a logical candidate for targeted therapies. But translating that concept into effective clinical treatments has been difficult. Rather than attempting to replace the missing FMR1 protein directly, the UCLA team investigated downstream molecular consequences of FMR1 loss to find alternative intervention points.
Using a mouse model that lacks FMR1, researchers applied cell-type-specific RNA sequencing to separately profile excitatory and inhibitory cortical neurons. This translatome approach revealed that many molecular pathways shift in different directions between the two cell classes, reflecting the complex excitation/inhibition imbalance in Fragile X. Among the genes dysregulated across both neuronal types, Rapgef4/EPAC2 stood out because it is a known FMRP (Fragile X mental retardation protein) target, enriched in the brain, and linked to neurodevelopmental function.
The team tested whether reducing EPAC2 activity could correct neural circuit dysfunction and behavioral deficits. In FMR1 knockout mice, genetic deletion of EPAC2 or treatment with a selective EPAC2 antagonist normalized cortical circuit activity and improved multiple behavioral measures—reducing tactile hypersensitivity, enhancing social interactions, and lowering seizure susceptibility.
Lead author Dr. Anand Suresh, a postdoctoral fellow in the laboratory of Dr. Carlos Portera-Cailliau at UCLA, noted that EPAC2’s consistent dysregulation across diverse neuronal types made it an especially attractive target. Because EPAC2 expression is largely confined to the brain, targeting it minimizes the chance of systemic side effects—an important consideration for future drug development and preclinical studies.
Importantly, the investigators observed that EPAC2 expression increases with brain maturation. This temporal pattern suggests that EPAC2-directed therapies may be effective across a wider age range than many developmental interventions, offering a potential path for treatment in older children, adolescents, and adults who already carry the diagnosis.
Key Questions Answered:
A: Direct gene replacement remains technically and clinically challenging. The UCLA team instead examined the molecular consequences of FMR1 loss and identified EPAC2 as a downstream protein whose inhibition can circumvent the primary mutation and correct neural circuit and behavioral abnormalities.
A: EPAC2 meets key therapeutic criteria: it is consistently elevated across both excitatory and inhibitory neurons despite their divergent responses to FMR1 loss, and it is predominantly brain-specific, reducing the risk of peripheral side effects from systemic drug exposure.
A: The data suggest not. EPAC2 levels increase as the brain matures, indicating that EPAC2-targeting approaches could benefit older children, adolescents, and adults, not only infants or very young children.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The original journal paper was reviewed in full.
- Additional context was provided by editorial staff.
About this Fragile X syndrome research news
Author: Will Houston
Source: UCLA
Contact: Will Houston – UCLA
Image credit: Neuroscience News
Original Research: Open access. Translatome profiling reveals opposing alterations in inhibitory and excitatory neurons of Fragile X mice and identifies EPAC2 as a therapeutic target by Anand Suresh et al., published in Neuron. DOI:10.1016/j.neuron.2026.04.032
Abstract
Translatome profiling reveals opposing alterations in inhibitory and excitatory neurons of Fragile X mice and identifies EPAC2 as a therapeutic target
Fragile X syndrome (FXS), the leading monogenic cause of intellectual disability and autism, is widely thought to result from an imbalance between excitation and inhibition in cortical circuits. Using cell-type-specific mRNA sequencing, the study profiled molecular alterations in cortical excitatory (Camk2a-expressing) and inhibitory (Pvalb-expressing) neurons in Fmr1 knockout mice, integrating transcriptomic findings with circuit and behavioral readouts to prioritize therapeutic targets.
The authors identified strong genotype-by-cell type interactions: many pathways were dysregulated in opposite directions between excitatory and inhibitory translatomes. Of 184 genes differentially expressed in both cell types, only Rapgef4 (EPAC2) was upregulated in Fmr1 knockout mice, known to be an FMRP target, enriched in brain tissue, and associated with neurodevelopmental processes. Pharmacological inhibition of EPAC2 in Fmr1 knockout mice restored cortical circuit function and improved multiple behavioral phenotypes, supporting EPAC2 as a candidate therapeutic target for Fragile X syndrome.